I’ve traded the markets for decades.
And I have yet to see anything as impressive as this.
After picking up beaten-down shares of ACADIA at just $1.05 and $1.24 in 2010, we just watched the stock hit a high of $43 a share.
That’s a four-year gain of 3,900% and 3,287%.
Every $5,000 invested is now worth well over $200,000 in five short years.
When we bought, no one wanted to touch this more than 80% off highs.
Now every one is running to buy.
And rightfully so… What this company is offering is a game-changer. Nuplazid could become the first drug approved in the U.S. to combat Parkinson’s disease Psychosis. According to the National Parkinson Foundation, between four and six million people worldwide suffer from Parkinson’s disease. About 40% suffer from PDP, characterized by hallucinations and delusions.
After a brief pullback, smart investors have been quick to buy shares of ACAD at the lows. News is ACADIA Pharmaceuticals (ACAD) just filed its New Drug Application for its Parkinson’s disease Psychosis (PDP) drug.
If ACAD has its drug approved, it could provide significant profit opportunity. ACAD has also requested Priority Review of NDA, which if granted would accelerate the review from ten months to just six months.
I believe it’ll move significantly higher.